

LABQUALITY



External Quality Assessment Program for *Mycoplasma genitalium*, drug resistance multiplex, nucleic acid detection

Labquality is announcing a new EQA scheme for *Mycoplasma genitalium*, drug resistance multiplex, nucleic acid detection. The scheme is suitable for nucleic acid assays detecting *Mycoplasma genitalium* and mutations in the 23S rRNA gene that are associated with resistance to azithromycin (macrolide antibiotic). The EQA samples should be analysed as regular patient samples. Participants submit their results through the electronic platform LabScala and results are processed by the EQA coordinator. Result evaluations including expert comments will be published in the final report distributed to the participants.

Round 1, 2023 will be a pilot study free of charge for a limited number of participants. The pilot round will open in September-October. Two rounds will be included in the program of 2024.

5254 *Mycoplasma genitalium*, drug resistance multiplex, nucleic acid detection

Samples: 3 swab samples
Distribution: 1, 2023 September/October – free-of-charge pilot study
Participation: Limited number of samples available
Registration: Please register by **August 15th, 2023** only via [this link](#).

Please note, if you have already registered through the general pilot registration link earlier this year, no further actions are needed.

For more information

Labquality's customer service info@labquality.fi or

Heidi Berghäll

R&D Manager

heidi.berghall@labquality.com

+358 50 356 0503